Charles E. Geyer, Jr, MD

Charles Geyer, MD, advises his peers on how to manage the grade 3 or higher toxicities and any serious adverse events seen in the clinical trial setting with adjuvant olaparib.

Charles Geyer, MD, discusses the potential impact of adjuvant olaparib on the treatment landscape for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Charles Geyer, MD, discusses the end point that was met within the OlympiA study.

Charles E. Geyer, MD, discusses the efficacy of olaparib in the OlympiA study of patients with BRCA-positive, HER2-negative high-risk early breast cancer.

Charles E. Geyer, Jr, MD, professor of medicine at Virginia Commonwealth University School of Medicine, associate director for clinical research and Harrigan, Haw, Luck Families Chair in Cancer Research at Massey Cancer Center, discusses the impact of pertuzumab (Perjeta) in the treatment of patients with HER2-positive breast cancer at the 2018 San Antonio Breast Cancer Symposium.